Regulation of colanic acid polysaccharide capsule synthesis in Escherichia coli requires the proteins RcsC and RcsB, in addition to several other proteins. By sequence similarity, these two proteins appear to be members of the two-component sensor-effector regulatory family found in bacteria. The present study characterizes the functional domains of RcsB. We have isolated mutations in rcsB that are able to suppress an rcsC "up" mutation (i.e., leading to increase in cps transcription) that normally results in constitutive expression of the capsule. In addition, constitutive capsule mutations in rcsB have been isolated. From the characterization of the mutants and by analogy to the three-dimensional structure of CheY, we have begun to define different domains of RcsB and to assign functions to them. A few of the constitutive capsule mutations were localized in an acidic pocket that has been proposed to play a crucial role in phosphorylation of RcsB. As seen in other two-component systems, an aspartate-to-glutamate substitution at the presumed site of phosphorylation of RcsB resulted in constitutive capsule expression. Lastly, several of our rcsB mutants were found to be allele specific (rcsC137 specific) for rcsC, suggesting a physical as well as functional interaction between RcsC and RcsB proteins.
Capsule production is a characteristic shared among many microorganisms. This extracellular layer of polysaccharide functions in many ways to aid in the survival of bacteria in various hostile environments. Among the capsule's varied functions are evasion of host immune defenses, prevention of desiccation, and microcolony formation, which includes providing a nutrient-rich environment for bacteria (5, 6) . Escherichia coli can synthesize over 70 different capsules (17) . One of these capsules, colanic acid or M antigen, causes cells to become extremely mucoid (10) . Colanic acid polysaccharide capsule synthesis in E. coli is encoded by the cps gene cluster, whose products function in polymerization, transport, and modification of the polysaccharide (24, 36) .
Based on genetic studies, sequence analysis, and preliminary biochemical characterization, a model for regulation of capsule synthesis has been proposed elsewhere (14) . According to this model, there are two pathways that regulate the synthesis of colanic acid capsular polysaccharide. Lon and RcsA compose one regulatory pathway. Lon is an ATP-dependent protease that degrades several proteins, including RcsA, which is a positive regulator of capsule synthesis (40) . RcsA is, therefore, limiting for capsule expression. The second point of control is provided by a two-component, environmentally responsive, regulatory pair of proteins (14, 38) . Sequence similarity identifies the two essential components of this pathway, RcsC and RcsB, as sensor and effector proteins, respectively (12, 38) . By analogy to other two-component regulators, RcsC may be a membrane kinase protein that activates RcsB by phosphorylating it and deactivates RcsB by dephosphorylating it. In most of the well-studied cases, the sensor also dephosphorylates the effector (19) . RcsC may be phosphorylating RcsB only after receiving a certain environmental signal(s). The phosphorylated and activated RcsB protein may then stimulate transcription of the target cps genes (14, 38) . Although it is known that RcsB is absolutely required for capsule expression, phosphorylated RcsB activates the cps genes to the maximum level only when RcsA is present (3, 14, 38) . Both RcsA and RcsB have been shown to be members of a family of regulatory proteins defined as the LuxR group (39) . Members of this family bind DNA and alter transcription by activating or repressing it. In addition, recent studies have suggested that RcsA and RcsB form heterodimers (21) . These results suggest that RcsA and RcsB may bind the cps promoter region together and activate transcription.
RcsF, a putative membrane protein, has been proposed to be a kinase that may exert its action through RcsB, possibly by phosphorylation. However, RcsF has no significant sequence similarity with any known sensor proteins (9) . The presence of a multicopy rcsC ϩ plasmid in cells carrying a multicopy rcsF ϩ plasmid markedly reduces the level of mucoidy (9) , which may indicate that RcsC acts as a phosphatase enzyme that dephosphorylates RcsB, thereby inactivating it. A mutation in rcsC, rcsC137, supports this proposed phosphatase activity of RcsC. rcsC137 is a recessive mutation which results in increased expression of the cps genes. It has been suggested (38) that this mutant lacks phosphatase activity and, therefore, is locked in a conformation that leads to constitutive activation of RcsB. In this model, RcsB is phosphorylated by other sensor kinases by cross-talk or perhaps by a low-level kinase activity that is still present in the mutant RcsC protein. Therefore, RcsC may exert both a positive effect and a negative effect on expression of the cps genes through RcsB. The results from our biochemical experiments suggest that RcsB can be phosphorylated by RcsC and another sensor protein, FixL, by cross-talk phenomena (unpublished results).
From the model, we propose that RcsB has three functions, namely, interaction with RcsC, interaction with RcsA, and interaction with the cps promoter. Because of the crucial functions of RcsB in activating cps expression, it was critical to investigate structure-function relationships of this effector protein. In this work, we characterize the functional domains of RcsB by genetic analyses. Two categories of mutations were isolated based on their effect on cps expression. We have taken advantage of the three-dimensional model of CheY in characterizing the different rcsB mutations.
MATERIALS AND METHODS
Bacterial strains, plasmids, bacteriophages, and growth conditions. The E. coli K-12 strains, plasmids, and bacteriophages used in this work are listed in Table 1 . All strains are derivatives of MC4100 (34) unless otherwise noted. Generally, cells were grown in Luria-Bertani (LB) broth at 37°C with shaking or on LB or tryptone broth (TB) agar plates. When necessary, media were supplemented with antibiotics at the following concentrations: ampicillin, 125 g/ml; kanamycin, 30 g/ml; and tetracycline, 15 g/ml. rcsA, rcsB, and rcsC mutations were introduced into the strains by P1 transduction with mini-or full Tn10 or Tn5 transposons that were closely linked or inserted into these genes. P1 transductions were performed as described by Miller (25) . Strains containing the rcsC multicopy plasmid pJB201 could be grown to an optical density at 600 nm of only 0.4 before the cells began to lyse. Strains containing the cpsB10::lacZ fusions were used to monitor capsule expression from the cps genes.
In addition to the strains described above, an rcsC rcsB cpsB::lacZ strain was constructed. To make this strain, SG21168 (rcsC10::⌬Kan) was lysogenized with phage SY14 (rcsB::⌬Tn10). This phage is a D69 derivative and, therefore, is Int Ϫ and unable to lysogenize by site-specific recombination at att. Lysogenization of this phage occurs by homologous recombination with the rcsB region of the chromosome. The resulting lysogens were screened for resistance to kanamycin (Kan r ) and tetracycline (Tet r ). A Kan r Tet r isolate was grown at 42°C to early log phase to induce the SY14 phage, plated on LB-kanamycin agar, and incubated at 42°C. Kan r colonies were tested for tetracycline resistance. Loss of SY14 was confirmed by cross-streaking against an SY phage as described by Silhavy et al. (34) . A P1 lysate on this SY s Kan r Tet r strain was made and used to transduce SG20781 (cpsB::lacZ) to Kan r and was subsequently tested for Tet r . The strain's genotype was confirmed by complementing the mutations with an rcsC137 rcsB ϩ phage, and the strain was labeled VS20322. Isolation of rcsB mut . A rcsB ϩ transducing phage (SB19) has been described previously (3) . SB19 was mutagenized by growing the phage in a mutD strain (LE30) as described previously (7, 34) . Twelve pools of mutagenized rcsB lysate were made (34) . Primary screening of the mutagenized rcsB phage lysates was performed by screening the mutagenized rcsB lysates on TB agar plates overlaid with top agar containing VS20191 (rcsB lon ϩ cpsB::lacZ) cells and 20 l of 40-g/ml 5-bromo-4-chloro-3-indolyl-␤-D-galactopyranoside (X-Gal). Wild-type rcsB (SB19) phage produced white plaques in this background assay. Mutant phages that yielded light, medium, or blue plaques were purified by picking up single plaques in TMG buffer (34) and vortexing to make a phage suspension. This suspension was spotted onto top agar containing the VS20191 strain and streaked with a platinum wire having a fine ball-shaped end until a homogeneous population of plaques was achieved. Plate lysate stocks were then made from well-isolated plaques by a protocol described by Silhavy et al. (34) . A total of 90 
pACYC184 ϩ rcsBD56N S. Gottesman rcsB mutants were isolated and designated rcsB "up" mutants (i.e., resulting in increased levels of cps transcription). The mutagenized rcsB phage lysate pools were also subjected to primary screening in an rcsC137 rcsB cpsB::lacZ strain (VS20300). Mutant phage isolates that produced lighter blue plaques than those of the wild type on TB X-Gal plates were purified by restreaking. Lysates of isolated plaques were made as described for rcsB up mutants. A total of 52 rcsB mutants were isolated and labeled rcsB "down" mutants (i.e., resulting in decreased levels of cps transcription).
Transfer of mutations from lambda to the bacterial chromosome. To obtain the newly created rcsB mutations in single copy in a cell so that more-consistent regulation results could be obtained, the rcsB mutations were transferred to the chromosome by lysogenization. Since the D69 derivatives carry chromosomal DNA at the BamHI site within the int gene, these phages are Int Ϫ and cannot lysogenize by site-specific recombination into the attachment site for (26) . Therefore, selection for lysogens with the SB19 phage carrying the rcsB gene should result in a single crossover event leading to insertion of the phage into the chromosome by homologous recombination. The up mutants were lysogenized into VS20191 (rcsB62::⌬kan cpsB::lacZ), and the down mutants were lysogenized into strain VS20300 (rcsB11::⌬Tn10 rcsC137 ompC::Tn5 cpsB::lacZ) according to the lysogenization procedure described by Silhavy et al. (34) . In general, the rcsB down mutant lysogens were unstable; in a few of the lysogens, up to 5% of the colonies that grew on TB plates containing X-Gal had mutated to a lighter color, and many had mutation frequencies of approximately 1%, which were calculated as ratios of numbers of lighter blue plaques to the total numbers of plaques. The mutation frequency was much higher when the lysogens were streaked on rich medium, such as LB, and there was a high number of mutants when they were streaked from stabs. Therefore, when lysogens were streaked from stored cultures, they were restreaked several times in order to achieve a relatively homogeneous population before subjecting the strains to ␤-galactosidase assays.
␤-Galactosidase assays. ␤-Galactosidase assays of the rcsB mut lysogens were performed as described by Miller (25) . For each mutant lysogen, the assay was performed in triplicate, and the average ␤-galactosidase activities were calculated. Approximately 33 rcsB mut /rcsB cpsB::lacZ lysogens that showed ␤-galactosidase values significantly greater than those of the wild-type parent lysogen were retained as rcsB up mutants. In addition, one lysogen that had the same specific units of ␤-galactosidase that the wild type (D10N) did was retained, since this mutant had yielded medium blue plaques. Similarly, approximately 21 rcsB mut /rcsC137 rcsB cpsB::lacZ lysogens demonstrating ␤-galactosidase values that were less than that of the rcsB ϩ lysogen were selected as rcsB down mutants.
DNA manipulations. The mutant rcsB genes were amplified from lysates by using the primers B18N2 (5Ј-GTGCAACTGGCGCAGG), which is located approximately 200 bp upstream of the putative RpoN-like promoter, and C19G8 (5Ј-ATCCGGCATTCAGTGC), which is located downstream of the rcsB gene, by PCR. The amplified DNA product was purified from the primers with a PCR purification kit (Qiagen). For each mutant, two reactions were performed, and the forward and reverse strands of the gene were sequenced to eliminate the possibility of identifying mutations due to PCR. Sequencing was performed with an Applied Biosystems 373 DNA sequencer. The sequences were analyzed with the Gap program of the University of Wisconsin Genetics Computer Group (8) software package.
Characterization of plasmid pWPC101. pWPC101 was constructed previously by site-directed mutagenesis (11) in order to replace the aspartate residue at amino acid 56 of RcsB with asparagine. To confirm this change, pWPC101 was sequenced by the dideoxy chain termination method (32) by using the Sequenase version 2.0 sequencing kit (U.S. Biochemicals). Transformation of the plasmid into various strains was performed by the method described by Cheung et al. (4) . Transformants were selected on LB ampicillin plates that were spread with 20 l of 40-mg/ml X-Gal solution. Plasmid pVS102 carrying the wild-type rcsB ϩ gene was used as a control.
RESULTS

Isolation of rcsB up mutations.
It has been shown that null mutations in rcsB eliminate synthesis of colanic acid capsule and cps::lacZ expression in either lon or rcsC137 strains (13) . These mutations can be complemented by a rcsB ϩ transducing phage. To isolate mutations in rcsB, rcsB ϩ was mutagenized in an mutD strain (LE30) and rcsB up mutants that stimulated cpsB::lacZ expression in an rcsB lon ϩ background (VS20191) were isolated. The mutation frequencies ranged from 0.45 to 1.6%, as estimated by the ratio of the number of darker-blue plaques to the total number of plaques as expected from mutD mutagenesis. Approximately 90 of these mutants that produced plaques that were darker blue than wild-type rcsB plaques in this primary screening were lysogenized in an rcsB lon ϩ cpsB::lacZ strain (VS20191). These lysogens were assayed for ␤-galactosidase activity in order to quantitate the effect of the mutation on the transcription of the cps genes. Approximately 33 rcsB mutations which resulted in a significant increase in cps transcription compared to that of the wild type were retained for further study. The fold increase column in Table 2 shows the increase in the ␤-galactosidase values of the rcsB up mutants in comparison to those of the wild-type rcsB (SB19) lysogen. In general, the ␤-galactosidase values correlated with plaque color, although there were a few exceptions, e.g., mutant B73 (carrying the D10N mutation) demon- strated no change in ␤-galactosidase value in spite of its strong plaque phenotype. These exceptions may be related to the instability of the lysogens. The instability of the rcsB down lysogens could be due to the excision of the prophage which results in chromosomal DNA that looks like the parental strain (VS20300).
Sequencing of rcsB up mutants. Sequencing of the rcsB up mutants was performed in order to locate the mutations. All of the rcsB up mutants subjected to sequencing contained point mutations within the open reading frame (ORF) of rcsB ( Table  2) . There were 17 different mutations among the 34 mutants that were sequenced, and several of the mutations were independently isolated several times. Mutations that were isolated more than once included D10N, D11N, F17L, I19V, D56E, P113L, P117S, A119T, A119V, D198N, and S206F. One of the most interesting mutations was D56E, since this is the proposed site of phosphorylation. When the same mutation was isolated more than once, only one mutant was chosen for further study. Because all of the point mutations were located within the 651 bp of the ORF of rcsB, the levels of the mutant RcsB proteins were expected to be very similar to that of the wild type. In fact, no significant differences in the amounts of RcsB were observed (data not shown). Therefore, the increases in cps expression levels in these mutants are not due to increases in the levels of transcription or translation of rcsB in the cell.
In addition to the point mutations identified by sequencing, analysis also showed that there was an error in the published rcsB sequence (38) . The correct sequence should have an additional cytosine residue at nucleotide 799 with respect to the published rcsB sequence. This C residue lies downstream of the ORF of rcsB within one of the two direct repeats found between the rcsB and rcsC genes (9, 38) .
Secondary screening of rcsB up mutants. The rcsB up mutants were subjected to several secondary screens by streaking the selected individual rcsB up mutant phages on specific strains carrying mutations in the regulatory genes related to capsule expression ( Table 2 ). The rationale for using the individual strains is given below.
Screening in an rcsB ϩ cpsB::lacZ strain (SG20781) was performed to test for dominance. If the mutations were recessive, white plaques would be obtained due to suppression by rcsB ϩ . However, as expected for gain-of-function mutations, all of the rcsB up mutations were found to be dominant to wild-type rcsB ϩ , as seen in Table 2 . Some of the mutations appeared to be codominant (D11N, P117L, K118E, A119T, A119V, and E196K). These results suggest that the rcsB up mutations stimulate cps::lac expression by (i) attaining a more active form due to enhanced interaction of RcsB with RcsC, (ii) enhanced interaction of RcsB with RcsA, or (iii) improved interaction of RcsB with the cps promoter.
For one of the secondary screens, an rcsC rcsB cpsB::lacZ (VS20322) strain was used in order to distinguish between mutations that were RcsC independent (blue on LB plus XGal) and those that were RcsC dependent (lighter blue on LB plus X-Gal) ( Table 2 ). In the RcsC-dependent mutations, RcsB may be phosphorylated more efficiently or dephosphorylated less efficiently by RcsC compared to wild-type RcsB. The mutations, were classified as RcsC dependent or RcsC independent based on comparison with screening in the rcsB cpsB::lacZ strain. These rcsB up mutations may only be partially dependent on rcsC. The partial dependence on rcsC could be explained by cross-talk phenomena. Thus, in the absence of rcsC, it is possible that RcsB is phosphorylated by other sensor kinase proteins, although to a lesser extent. rcsB up mutants D11N, H12Y, F17L, I19V, P113L, P117L, K118E, A119V, K187R, and S206F were found to be RcsC dependent, whereas D10N, D11A, D56E, P117S, A119T, E196K, and D198N were RcsC independent. We believe that although the rcsA or rcsC dependence of certain rcsB up alleles is variable by only a small degree in most cases, these differences were significant.
The rcsB up mutants were subjected to screening in an rcsC137 rcsB cpsB::lacZ strain (VS20300). rcsC137 increases the levels of cpsB::lacZ expression and capsule synthesis in lon ϩ hosts. Studies with rcsA rcsC137 and rcsB rcsC137 double mutants have indicated that both rcsA ϩ and rcsB ϩ are essential for high-level expression in rcsC137 hosts, suggesting that the rcsC137 gene product does not act as a bypass for the RcsARcsB pathway but that it may affect the activities of these proteins. Although some residual capsule synthesis is observed in an rcsC137 rcsA-null mutant strain, rcsC137 rcsB-null mutants eliminate capsule expression (3). This suggests that RcsC primarily exerts its action through RcsB. RcsC137 is presumably mutated such that it lacks phosphatase activity and, hence, may be locked in a state that leads to constitutive activation of RcsB (38) . Screening in the rcsC137 rcsB cpsB::lacZ strain was performed to test whether any of the rcsB up mutations were specific for rcsC ϩ . Since the rcsC137 mutation results in increased capsule expression with wild-type rcsB, a decrease in the level of cpsB::lacZ expression in an rcsC137 cpsB::lacZ strain with an rcsB up mutant phage suggests that the particular rcsB mutation is specific for rcsC ϩ . As shown in Table 2 , the D11N, H12Y, and P117L mutations appeared to result in a decrease in cpsB::lacZ expression compared to expression in the rcsC ϩ cpsB::lacZ strain. Therefore, these may represent rcsB mutations that are allele specific for rcsC ϩ . As expected, these three mutations are RcsC dependent ( Table 2) .
The rcsB up mutations were also subjected to secondary screening in an rcsA rcsB cpsB::lacZ strain (VS20323) to determine which of the rcsB up mutations are dependent on RcsA. Most of the rcsB up mutations were found to be RcsA independent except for H12Y, F17L, K118E, A119T, K187R, and S206F (Table 2) .
Screening of rcsB up mutations was also performed with a lon rcsB cpsB::lacZ strain (VS20189). Since Lon, an ATPdependent protease, degrades RcsA, the level of expression of the cps genes normally increases dramatically in lon mutant hosts (41) . This pathway of stimulation does not appear to require activated RcsB, because cpsB::lacZ stimulation is independent of rcsC (41) . Therefore, RcsC-RcsB interaction may not be required for increased capsule expression in lon mutations. However, because lon mutant cells still require RcsA-RcsB interaction for increased cps expression, rcsB up mutations mutated for improved interaction with RcsA should show increased cps transcription in the lon rcsB cpsB::lacZ strain. This class of rcsB mutations cannot be distinguished from wild-type rcsB, since wild-type rcsB also results in increased capsule expression in a lon mutant. Therefore, no change in cpsB::lacZ expression suggests that the mutations are independent of RcsA, which in fact was the case for most of the rcsB up mutations (Table 2) . Only the S206F, I19V, P117S, K118E, and A119V mutations appeared to be dependent on RcsA by this screening. Two of these mutations (K118E and S206F) appeared to be dependent by screening in the rcsA mutant strain, but the other three did not. It is important to note that the plaques in the lon strain had an unusual morphology in that they were much larger and diffused; hence, it was difficult to interpret the plaque color confidently. In this case, therefore, only a downrating of at least two degrees or an uprating of two degrees should be considered significant. At this stage, we do not have a good explana-tion for the K187R mutation that results in a decrease in the level of cpsB::lacZ expression by two degrees; this is being investigated further. These differences indicate that the system is complex and that the two screenings may be affected by different components involved in capsule regulation.
Lastly, the rcsB up mutations were subjected to secondary screening in an rcsF rcsB cpsB::lacZ strain (VS20325). RcsF has been proposed to act as a kinase of RcsB (9); therefore, it was important to test the mutations for dependence on RcsF. Most of the mutations were dependent on RcsF, with only six (D10N, D11A, D56E, P117S, A119T, and D198N) being independent (Table 2) . Interestingly, the mutations that were RcsF dependent were also dependent on RcsC. This suggests that RcsF may act on RcsB at sites that are similar to those that are involved in interaction with RcsC.
Isolation of rcsB down mutations. Primary screening of the pools of mutagenized rcsB ϩ phage in an rcsC137 rcsB cpsB:: lacZ strain (VS20300) on LB agar containing X-Gal yielded plaque phenotypes that were lighter blue than those of wildtype rcsB ϩ . These phenotypes indicated suppression of the constitutive rcsC137 mutation by mutant rcsB. rcsB mut plaques demonstrating phenotypes of a lighter blue color than that of the wild type were purified as rcsB down mutations. The mutation frequency ranged from 5 to 14%, which was much higher than expected. This may have been due in part to difficulty in distinguishing wild-type blue plaques from those that were only slightly reduced in the intensity of blue. Because of this, it is possible that some wild-type phages were mistakenly categorized as mutant phages. Therefore, isolation of the down mutations was comparatively more difficult than that of the up mutations.
As predicted, there were many more rcsB down mutations with white plaque phenotypes than those with light-blue phenotypes, since phages carrying an rcsB null mutation will fail to complement the rcsC137 rcsB cpsB::lacZ host. These white mutations were not tested further, under the assumption that they represented complete inactivation of the rcsB gene.
The pool of rcsB mutations which suppressed the rcsC137 mutation in the primary screening was lysogenized in the rcsC137 rcsB cpsB::lacZ strain. ␤-Galactosidase assays of each of the lysogens were performed to quantitate the effect of the mutation on cps transcription. Twenty-one rcsB mutations that demonstrated a decrease in the level of cps transcription compared to that of the wild type were retained for further study.
Sequencing of rcsB down mutations. Among the 21 rcsB down mutations that were subjected to sequencing, only 3 mutations that contained mutations within rcsB were identified. All three of these had substitutions within the ORF of rcsB. Mutant A58 contains a point mutation which results in the substitution of serine for proline at amino acid no. 92 of RcsB (P92S), mutant A61 has a valine-to-alanine substitution at amino acid no. 85 (V85A), and mutant A38 contains a substitution of proline for leucine at amino acid residue no. 205 (L205P) ( Table 3) . Presumably, the other 18 isolates had mutations somewhere else on the phage or were unmutated phages. This supports the idea that the higher mutation frequency seen in the screening for down mutations was due to false-positive results.
None of the rcsB up and down mutations were found in the regulatory region of the rcsB gene, indicating that the phenotypic changes are due to alterations in the conformation of the RcsB protein rather than expression of the rcsB gene. Quantification of the amount of RcsB protein in the mutant lysogens did not show any significant differences in RcsB protein levels compared to those of the wild type (data not shown).
Secondary screening of rcsB down mutations. The rcsB down mutations were screened in two strains to categorize them into different groups: those showing interaction with RcsA, interaction with RcsC, and interaction with the promoter.
The first strain used for secondary screening of the down mutations was lon rcsB cpsB::lacZ (VS20189). The rationale for using this strain was described under the secondary-screening results for the rcsB up mutations. This screen should distinguish rcsB mutations that are mutated for RcsC interaction from those affecting either RcsA interaction sites or cps promoter interaction sites. The P92S and V85A mutations demonstrated decreased cps expression in this strain compared to that of the wild type (Table 3) , and therefore, they are likely to be altered in their ability to interact with RcsA. The cpsB::lacZ expression level of the L205P mutation is unchanged in this strain.
The second screening was performed in rcsA62 rcsB cpsB::lacZ. rcsA62 is a dominant allele encoding RcsA*, which increases the level of capsule expression even in lon ϩ hosts. RcsA* differs from wild-type RcsA in the substitution of methionine 145 by valine (39) . It has been demonstrated that RcsA* is more stable than RcsA in lon ϩ hosts only when RcsB is present, suggesting that RcsA* interacts better with RcsB (14, 39) . Therefore, if the rcsB down mutation affects RcsBRcsC interaction, no change from the wild-type phenotype would be seen. In this screening, the level of cpsB::lacZ expression in all three of the mutations was less than that of the wild type (Table 3) . Therefore, the results from the screening of the P92S and V85A mutations in this strain support the earlier interpretation that these mutations are affected in their interaction with RcsA. Classification of the L205P mutations is not clear. In summary, based on the secondary-screening results, the mutations were assigned to two different categories, with L205P in one group and the P92S and V85A mutations in the other.
Phenotypic effect of the RcsBD56N mutation. Because we obtained mutations of the up class at residue 56 (D56E), we wanted to examine the effect of another mutation at this position that had been constructed previously. This mutation was obtained by site-directed mutagenesis and resulted in a substitution of the conserved aspartic acid residue at amino acid 56 of RcsB with asparagine (D56N) (11) . By analogy to other effector proteins, this is the presumed site of phosphorylation (1, 20) . To analyze the phenotypic effect of this mutation, the plasmid carrying this mutated rcsB, pWPC101, was transformed into four different strains. The results of these transformations are shown in Table 4 . The rcsC137 mutation has been shown to increase the level of capsule expression even in lon ϩ hosts (3). When rcsC137 rcsB and rcsC137 rcsB cpsB::lacZ cells were transformed with a wild-type rcsB gene (pVS102), the level of capsule expression was high, whereas cells transformed with the mutant rcsB gene (pWPC101) showed no capsule expression. Similar results were seen when a lon rcsB cpsB::lacZ strain was transformed with the two plasmids; the wild-type rcsB gene allowed high levels of cps expression, and the mutant rcsB gene did not. It has been shown previously that in cells carrying rcsB ϩ on a multicopy plasmid, the requirement for RcsA for capsule synthesis can be partially bypassed (3). A phenotypic effect similar to those in the rcsC137 and lon strains was observed in the rcsA strain; although wild-type rcsB resulted in elevated cps expression, mutant rcsB had no positive effect on cps expression. From these results, it is evident that the D56N form of RcsB fails to activate transcription from the cps genes, whereas wild-type rcsB retains this ability.
DISCUSSION
We have isolated rcsB mutations that both decrease and increase the level of cps transcription (down and up mutations, respectively) compared to that of the wild-type gene. The rcsB down mutations suppressed an rcsC up (rcsC137) mutation, whereas the rcsB up mutations stimulated capsule expression in a wild-type background. Based on secondary screening in different mutant strains and sequence analysis, the mutations were categorized into different groups. According to the model, these functions include (i) interaction with RcsC, (ii) interaction with RcsA, and (iii) interaction with the cps promoter. In our interpretation, some of the mutations are affected in their interactions with RcsC and some of these demonstrate allele specificity.
RcsB shares sequence similarity in its N-terminal domain with effectors such as CheY, OmpR, NtrC, PhoB, VirG, FixJ, AlgR, DegU, UhpA, and NarL. This domain also includes the two conserved aspartic acid residues (amino acids 11 and 56 of RcsB) (38) . RcsB has more extended sequence similarity in its C-terminal domain to the subfamily of regulators comprised of FixJ, NarL, DegU, and UhpA (14, 38) .
Because of the conservation among the many response regulators, the domains defined by the rcsB mutations were compared to the known crystallographic structure of CheY, the effector protein involved in chemotaxis regulation (Fig. 1) . CheY, which is made up of 128 amino acid residues, is compactly folded in a (␤/␣)5 manner, where all five ␤-strands are in a parallel ␤-sheet, with the topology ␤2␤1␤3␤4␤5. Much of the two outermost strands (␤2 and ␤5) is solvent accessible (42) .
Sequencing of the mutations revealed that the mutations were localized into four domains of RcsB. The first domain included amino acids 10 to 19 and 56. Upon alignment of RcsB with CheY by using the Gap program of the Genetics Computer Group software (8), D10 and D11 of RcsB aligned with the D12 and D13 residues of CheY, respectively (Fig. 1) . These two aspartic acid residues are highly conserved among response regulators and, from the crystallographic structure of CheY, are known to contribute to the formation of the acidic pocket by projecting toward the site of phosphorylation. The D11A mutation of RcsB may confer a conformational change similar to that of the D13K mutation of CheY (1, 2), both of which result in constitutive phenotypes. It is possible that these two mutant proteins assume the active form without being phosphorylated. This is supported by the secondary screening showing that this mutation was rcsC independent. It is very likely that the D10N mutation has the same effect as that of the D11A mutation on conformation.
Based on secondary screening, the D10N and D11A mutations appeared to be constitutively active in promoting transcription of the cps genes in all of the strains. It is possible that the D11A form causes or allows formation of the active and phosphorylated conformation of the protein because of the nonpolar nature of alanine. Unexpectedly, when the D11 residue was changed to asparagine, it had a phenotype very different from that of the D11A mutation. The D11N mutation was still responsive to RcsC and RcsF, indicating that this change does not greatly alter the ability of RcsB to interact with RcsC or RcsF. This suggests that in the D11N mutation, the acidic pocket was still able to function. Interestingly, this mutant results in decreased cps expression in the rcsC137 strain compared with that of wild-type rcsC, suggesting that it interacts better with wild-type RcsC than RcsC137. This indicates that D11N is specific for rcsC ϩ (RcsB-RcsC interaction) and, hence, supports the proposed RcsC interaction function of RcsB. In brief, we speculate that D10 and D11 may be involved in forming an acidic pocket similar to CheY and probably aid in the interaction of RcsB with RcsC and/or RcsF. In addition, these two residues must play a critical role in RcsB function, since the D10N and D11N mutations were independently isolated several times.
The other mutations that are close to the domain defined by the D10 and D11 mutations, H12Y, F17L, and I19V, should be more distal to the acidic pocket, and as expected, they resulted in increased capsule expression (as seen by ␤-galactosidase values) to a lesser degree than that of the D11 mutations. Similarly to the D11N mutation, all three of these mutations are dependent on RcsC and RcsF. In addition, the H12Y mutation appears to be rcsC137 specific for RcsC interaction, since it shows decreased expression in the rcsC137 strain in- stead of increased expression in the presence of wild-type RcsB.
The final mutation that defines the first domain was an alteration of the conserved aspartate residue, D56, that aligns with the known site of phosphorylation of CheY, D57 (31) (Fig. 1) . This aspartate residue is conserved throughout the family of bacterial response regulatory proteins sharing sequence similarity at the amino-terminal region (28) . This conserved aspartate has also been shown to be the site of phosphorylation in several response regulators, including VirG (18) and NtrC (19) , and is presumed to play an important role in regulating responses to diverse environmental signals. By analogy to CheY, all of the rcsB mutations in the first domain are located in or distal to the acidic pocket of RcsB (Fig. 1) . This is equivalent to the clustering of the CheY mutations near the site of phosphorylation (1, 22) . This implies that the three aspartic acid residues of RcsB (D10, D11, and D56) are important for the protein, such that alterations of these residues may allow the protein to resemble the phosphorylated form of the protein.
Although phosphorylation is the required primary event in the activation of CheY (15, 16) and, presumably, all response regulators, phosphorylation and activation can be unlinked. The two most interesting types of phosphorylation mutations are (i) phosphorylatable but not active and (ii) nonphosphorylatable but constitutively active. A good example of the latter category is the RcsB D56E mutation, which appeared to be constitutive in all of the strains in which it was screened, indicating that it does not need RcsC, RcsF, or RcsA for its activity. Substitution of glutamate for the conserved aspartate has also been examined in other response regulators: CheY (1), VirG (29) , and NtrC (20) . In all of these cases, the change to glutamate resulted in constitutivity. In the nitrogen regulatory system, NtrC acquires a phosphate group from NtrBphosphate (19, 27) and NtrC-P catalyzes ATP hydrolysis and, thereby, isomerization of closed complexes between the 54 holoenzyme and the glnA promoter to open complexes (33) . The site of phosphorylation of NtrC is aspartate 54 (19) , and when it is changed to glutamate, this mutant NtrC activates transcription constitutively, in the absence of NtrB. The D54E substitution inactivates the phosphate-accepting activity of NtrC but mimics phosphorylation by allowing NtrC to hydrolyze ATP and to function as a transcriptional activator (20) . Thus, the D56E form of RcsB, which activates transcription of the cps genes constitutively, will be interesting to test for phosphorylation by RcsC in vitro. We presume that it will be nonphosphorylatable.
The conserved aspartate residue of NtrC has also been mutated to alanine and asparagine. These forms of NtrC are not detectably phosphorylated in vitro and cannot activate transcription in vivo (20) . This is similar to the in vivo results seen for the D56N form of RcsB encoded by pWPC101. The D56N form of RcsB needs to be tested for phosphorylation directly. It is likely that RcsB-D56N cannot be phosphorylated and, therefore, cannot activate transcription.
The second domain of RcsB is defined by the down mutations V85A and P92S and compares to CheY mutations that are located in the loop following the ␤4 strand that describe a spatially contiguous surface adjacent to the active site (30, 35) . These two mutations flank the conserved T87 residue that has been proposed to function in CheY as the proton donor to the active site by contacting D57 in the presence of magnesium ions (23) . Since our activity assays were performed in vivo with the V85A and P92S mutations and resulted in a very low level of capsule expression, these mutations must have a low level of activity even in the presence of Mg 2ϩ . It is possible that these two residues help T87 contact D56 in RcsB, as with CheY. This domain may also be involved in interacting with RcsA, since these mutations resulted in a reduced level of cps expression even in a lon mutant strain.
The third domain included mutations that spanned amino acids 113 to 119. Although the CheY structure was used as a paradigm in assigning structure-function relationships for RcsB, the sequence similarity between these two proteins diverges after the conserved K109 residue. Therefore, the effect of mutations in this third domain on the structure of RcsB is less clear. It is possible that the domain defined by mutations in this part of the protein constitutes a hinge region between the phosphorylation and the DNA binding sites such that it functions in coordinating the phosphorylation signal to the DNA-binding domain. The extent of the bend in the hinge region may dictate the level of communication between the input domain (N terminus) and output domain (C terminus). The presence of two proline residues in this putative hinge region is likely to contribute to the beta turn in the secondary structure, thereby allowing formation of a hinge. The proline residues at 113 and 117 are clearly critical residues for RcsB function, since mutations in these residues were independently isolated several times. These proline mutations are RcsA independent, whereas the wild-type RcsB is dependent on RcsA for maximal cps expression. From these results, we speculate that RcsA may be involved in communicating between the input and the output domains.
The fourth and last domain defined by the mutations ranged from amino acids 187 to 206 and included both up and down mutations, near the C terminus of the protein. This domain lies just outside the domain (171 to 185) that has been proposed to have the helix-turn-helix motif involved in DNA binding (39) . Although no mutations were found in the putative helix-turnhelix region, the fourth domain defined by five mutations may have context effects on the helix-turn-helix motif. Among these mutations, only D198N is constitutive, suggesting that this mutation may already be in the conformationally active form of the protein, without being phosphorylated. The other four mutations respond to at least one other regulator, indicating that they have a more minor effect on the protein's conformation than D198N. The rcsB down mutation, L205P, may be either an RcsC interaction mutation or a promoter interaction mutation. It is difficult to distinguish between these two categories, since screening in an rcsC strain will not reveal any additional information because, normally, the level of capsule expression is low in cells carrying a null mutation in rcsC. It is interesting that both up and down mutations were isolated in this region.
Surprisingly, we did not obtain a mutation at K109 of RcsB, which is an absolutely conserved residue among the response regulators. K109 from the ␤5 strand in CheY is critical for contacts with the acidic pocket residues; K109 has its side chain in a fully extended configuration and forms a firm hydrogen bond to the carboxyl group of D57 (31, 42) .
In general, most of the up mutations were found to be independent of RcsA, as seen by screening in an rcsA rcsB cps::lacZ strain, which suggests that RcsA may act essentially as an accessory factor in stimulating capsule expression. There has been genetic evidence suggesting that RcsA may act either directly or indirectly through RcsB to activate transcription of the cps genes (3, 39) . Previous work has also suggested that RcsA acts by directly interacting with RcsB. In fact, recently RcsA has been shown to form heterodimers with RcsB (21) . Genetic evidence also suggests that RcsA and RcsB together form multimers and activate transcription of the cps genes (32) . There is preliminary evidence suggesting that RcsA alone can bind the promoter region of the cps genes (37a). From these observations, we speculate that RcsA may have two roles: first, it interacts with the cps promoter by itself and/or interacts with phosphorylated RcsB and helps RcsB bind the promoter region to highly stimulate capsule expression; second, RcsA may affect RcsC-RcsB interaction. The fact that most of the rcsB up mutations are RcsA independent suggests that the mutated form of RcsB may interact very well with RcsC and, therefore, that RcsA is not needed in the RcsBRcsC interaction.
Experiments are currently under way to biochemically characterize some of the rcsB down and up mutations to aid in determining the functions of the various domains of RcsB. This involves performing in vitro and in vivo phosphorylation assays. It will also be interesting to analyze the up mutations that appeared to be constitutive in the in vitro transcription and gel mobility shift assays. We would expect them to bind very well to the cps promoter region without being phosphorylated.
Lastly, demonstration of the allele specificity of some of the rcsB up mutations for rcsC argues that RcsB and RcsC interact not only functionally but also physically. The search for more clearly defined allele-specific suppressors of rcsB up mutations represents the next step in this project. Physical interaction based on the lock-and-key mechanism can be demonstrated if an allele-specific mutation in rcsB, which results in an increased level of cps transcription, could be suppressed by a compensatory mutation in rcsC, thereby decreasing the level of cps transcription.
